Patented Meriva® Complex May Reduce Eye Inflammation
Lee Swanson Research Update
Uveitis is an inflammation involving the interior of the eye that in some cases can lead to blindness. Symptoms of RAU—also termed iritis—are pain, redness, photophobia and, to a variable degree, decreased vision.
To evaluate a possible beneficial role of Meriva for the adjunctive therapy of RAU, two tablets containing 600 mg of Meriva each were administered daily for 12 months to 112 patients. The patients had been diagnosed with RAU for at least two years before the beginning of the trial, and during which they had suffered one to four relapses per year.
Within the 106 patients who completed the study, only 19 (18%) had relapses. An improvement in symptoms including ocular pain and blurring of vision was also observed, and 86% of patients reported a subjective systemic well-being, progressively developed after four to six weeks of treatment. Moreover, the study showed that Meriva was well tolerated, since 90% of the patients enrolled completed the one-year follow-up.
Commenting on the results of the study Prof. Giovanni Appendino said, "This is the first large and controlled clinical study that demonstrates the efficacy of curcumin in eye relapsing diseases like anterior uveitis. It confirms the important anti-inflammatory activity of curcumin, and the same authors suggest that this could be useful also in other eye inflammatory and degenerative eye pathologies, like dry eye, maculopathy, glaucoma, allergic conjunctivitis and diabetic retinopathy."
Clinical Ophthalmology 2010(4):1201-1206, 2010
- Company
- Contact Us
- About Us
- Help Desk
- Job Opportunities
- Guarantees
- Policies
- What's New
- Newsroom
- Security
- Mobile Site
April 2011